-
Expanding upon their earlier study that demonstrated that spouses of hypertensive patients are more likely to be hypertensive themselves, these British researchers studied couples to determine whether other illnesses exhibited the same association.
-
Among patients being evaluated for chronic cough, women are more sensitive than men to inhalation of tussive agents.
-
GlaxoSmithKline is expected to launch a new drug for benign prostatic hypertrophy in December. Dutasteride is a 5 alpha-reductase inhibitor, which was previously approved in November 2001 but not launched.
-
Debate over the cardiovascular effects of COX-2 inhibitors has raged
for more than a year since a special communication was published in
JAMA last August suggesting an increase in cardiovascular events with
rofecoxib (Vioxx). Now a large retrospect, the cohort study from the
Tennessee Medicaid program seems to confirm the prothrombotic effects
of rofecoxib, at least in high dose.
-
This study assessed the effectiveness of oral melatonin taken in different dosage regimens for alleviating jet-lag after air travel across several time zones.
-
Efficacy of Handrubbing with Alcohol-Based Solution vs. Standard Handwashing with Antiseptic Soap: Randomized Clinical Trial; A Program To Prevent Functional Decline in Physically Frail, Elderly Persons Who Live at Home; Treatment of Chronic Painful Diabetic Neuropathy with Isosorbide Dinitrate Spray
-
The 12-lead ECG and accompanying rhythm strip in the Figure were obtained from an 84-year-old man who presented to the Emergency Department with acute dyspnea from pneumonia and heart failure. Whats going on?
-
Park and colleagues have noted adverse lipid profiles in patients with rheumatoid arthritis (RA). Since inflammation may be associated with atherosclerosis, Park et al sought to determine the effects of treating RA with antirheumatic drugs on the abnormal lipid levels.
-
Silverman and colleagues used the emergency departments in 8 hospitals to assess the role of MgSO4 in acute asthma in a sizeable number of patients (n = 248).
-
A new aldosterone receptor antagonist has been approved by the FDA. Eplereone, a selective aldosterone receptor antagonist, is the first approval in this class since the introduction of spironolactone close to 3 decades earlier.
